Glesatinib Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

Glesatinib is a TKI that targets tumors with MET and AXL alterations.

Clinical Use

Nonclinical models have shown glesatinib to be effective in MET exon 14 skipping mutations. It is currently being evaluated in phase II trials in NSCLC patients with MET alterations.

Glesatinib Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Glesatinib Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
TargetMol Chemicals Inc.	+1-781-999-5354; +17819995354	marketing@targetmol.com	United States	32466	58
TargetMol Chemicals Inc.	+17819995354	marketing@targetmol.com	United States	19956	58
Amadis Chemical Company Limited	571-89925085	sales@amadischem.com	China	131956	58
Shanghai Sphchem Co., Ltd.	021-56491756 13512199871	2819742715@qq.com	China	4000	55
BOC Sciences	1-631-485-4226; 16314854226	info@bocsci.com	United States	9920	65
Sichuan Wei Keqi Biological Technology Co., Ltd.	028-81700200 18116577057	3003855609@qq.com	China	7750	56
Shanghai BetterBioChem Co., Ltd.	+86-18017644823	sales@betterbiochem.com	China	325	58
TargetMol Chemicals Inc.	4008200310 15002144251	marketing@tsbiochem.com	China	24959	58
Shanghai Tachizaki Biomedical Research Center	18014399201	sales@chemlab-tachizaki.com	China	2945	58
Nantong QuanYi Biotechnology Co., Ltd	0513-66337626 18051384581	sales@chemhifuture.com	China	6000	58

---

• Glesatinib
• Glesatinib (MGCD-265
• Benzeneacetamide, 4-fluoro-N-[[[3-fluoro-4-[[2-[5-[[(2-methoxyethyl)amino]methyl]-2-pyridinyl]thieno[3,2-b]pyridin-7-yl]oxy]phenyl]amino]thioxomethyl]-
• 936694-12-1
• C31H27F2N5O3S2